`
`+ Key Findings
`+ Awareness and Trial
`♦ Special Topics
`+ Product Perceptions
`+ Product Usage
`♦ Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`2
`
`SANOFl3 90330508
`
`PTX-0739.0002
`Sanofi Exhibit 2146.002
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`Sales Force Tracking Study
`
`Physician ATU Tracking Study
`
`This study focuses on the product
`perceptions of the target audience
`
`..
`
`This study focuses on specnfic sales
`force interactions
`
`8/29/07 — 9/4/07: Sample n = 201
`
`*8/29107 — 10/19/07: Sample n = 682
`
`Humalog 75/25 or 50/50
`Total
`
`Lantus
`
`Byetta
`
`Levemir
`
`Novolog 70/30
`
`Januvia
`
`In the Sales Force Tracking Study, the goal is to interview physicians as close to the
`product detail as possible -) 70% of respondents were surveyed within 24 hours of their
`last detail, while the remaining 30% were surveyed within 2-7 days
`
`
`
`CONb'iUEN'i'LAL
`
`Note: Recruiting database sourced from POA2 2007, quintiles 3-5 targets in the Select Insulin Market. *69 PCPs and 73 Endos teokthe survey for
`multiple companies. Responses for non-quota group questions are taken from theirfirst survey.
`
`4
`
`SANOEL3_90330810
`
`PTX-0739.0004
`
`Sanofi Exhibit 2146.004
`
`Mylan v. Sanofi
`lPR2018-01675
`
`
`
`
`
`
`
`•
`
`Introduction
`
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`7
`
`SANOFl3 90330c l3
`
`PTX-0739.0007
`Sanofi Exhibit 2146.007
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`♦ Appendix
`
`········•···•·········••1
`
`CONYlUJ<.;N'l'lAL
`
`15
`
`SANOFl3 90330c2l
`
`PTX-0739.0015
`Sanofi Exhibit 2146.015
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Differences Between Lantus and Levemir: PCP
`
`Biggest Difference, Aside from Pen Devices
`
`Single Greatest Lanius Advantage over Levemir
`(Excluding Cost/ Formulary Status)
`
`Single Greatest Levemir Advantage over Lanius
`(Excluding Cost I Formulary Status)
`
`CONYlUJ<.;N'l'lAL
`
`Source: COMPASS Physician ATU Tracking Study
`Note Data are weightea by reach. Weighted percent of physicians shown for open-ended guestions. LAN 19: Aside from differences in pen devices,
`what do you consider to be the key difference between Lantus and Levemir? LAN1 OC A: Excluding cost and formulary status, what do you consider
`to be the single, greatest advantage of Lantus over Levemir? LAN10C B: Excluding cost and formulary status, what do you consider to be the single,
`-
`greatest advantage of Levernir over Lantus?
`
`56
`
`SANOFl3 90330562
`
`PTX-0739.0056
`Sanofi Exhibit 2146.056
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`-
`Attribute Importance & Overall Product Performance
`-
`Lantus vs. Levemir
`
`- Message Association
`♦ Product Usage
`• Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`58
`
`SANOFl3 90330564
`
`PTX-0739.0058
`Sanofi Exhibit 2146.058
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`-
`Product Choice Drivers
`-
`Treatment Pathway
`•
`Introduction
`
`Insulin Focus
`•
`• Byetta and Januvia Focus
`• Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`···············• 1
`
`83
`
`SANOFl3 90330589
`
`PTX-0739.0083
`Sanofi Exhibit 2146.083
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`CONYlUJ<.;N'l'lAL
`
`Source: COMPASS Sales Force Tracking Study
`Note: TXP5: Length of time controlled on this therapy before switching to next therapy. TXP6: HbA 1c level at which you alter the
`patient's therapy. • Average line of therapy and length of time until insulin include only physicians who initiate insulin in lines 1-6
`(exclude those who refer patient prior to insulin). Patient 1 profile revised Sep-Oct '07.
`
`SANOFl3 90330590
`
`PTX-0739.0084
`Sanofi Exhibit 2146.084
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`-
`Product Choice Drivers
`-
`Treatment Pathway
`•
`Introduction
`• All Product Overview
`
`• Byetta and Januvia Focus
`• Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`91
`
`SANOFl3 90330597
`
`PTX-0739.0091
`Sanofi Exhibit 2146.091
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`-
`Product Choice Drivers
`-
`Treatment Pathway
`•
`Introduction
`• All Product Overview
`•
`Insulin Focus
`
`• Sales Force
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`96
`
`SANOFl3 90330902
`
`PTX-0739.0096
`Sanofi Exhibit 2146.096
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`
`- Resources & Activities
`-
`Sales Rep Ratings
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`104
`
`SANOFl3 90330910
`
`PTX-0739.0104
`Sanofi Exhibit 2146.104
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`- Messaging
`
`Sales Rep Ratings
`-
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`•!·•·················••1
`
`108
`
`SANOFl3 90330914
`
`PTX-0739.0108
`Sanofi Exhibit 2146.108
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`- Messaging
`- Resources & Activities
`
`♦ Appendix
`
`CONYlUJ<.;N'l'lAL
`
`115
`
`SANOFl3 90330921
`
`PTX-0739.0115
`Sanofi Exhibit 2146.115
`Mylan v. Sanofi
`IPR2018-01675
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
